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Abstract 
 Background: People with type 2 diabetes are threefold affected by 
cardiovascular disease (CVD) compared with non-diabetics. Many studies 
reported the absence of traditional CVD risk factors in a substantial portion 
of individuals experiencing clinical vascular events. Novel risk markers for 
CVD are often said to add independent predictive value for risk prediction. 
Objective: In the present study we evaluated different CVD risk factors 
based on high-sensitivity C-reactive (hs- CRP) protein quartiles among 
diabetics and non-diabetics population.  
Methods: In this population- based cross- sectional study, we recruited a total 
of one-hundred and nine participants (64 type 2 diabetics and 45 healthy 
controls). Venous blood sample collected from each subject. Body weight 
and height were measured and body mass index (BMI) was calculated. 
Biochemical analytes were measured according to standard procedures. Data 
analyzed using SPSS software.  
Results: Mean serum hs-CRP levels were significantly higher among 
diabetics (2.3 mg/l) compared to controls (1.8 mg/l; P = 0.019). Moreover, 
the 3rd & 4th quartiles of hs-CRP were characterized by more frequency of 
diabetes as well as hypertension. The percent of participants with diabetes or 
hypertension seemed positively related to hs CRP concentrations. Lipid 
profile analysis revealed the highest levels of LDL-C and Apo B in 4th 
quartile hs-CRP. In addition, participants in the 4th quartile hs-CRP were 
characterized by the highest age, BMI, plasma glucose. However, there was 
no clear association between levels of hs-CRP and the HbA1c, TC, TG, 
HDL-C, and Apo A1.  
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Conclusion: Measurement of hs-CRP in diabetic patients might provide 
useful information for development of atherosclerosis and cardiovascular 
disease and help in early intervention. 
 
Keywords: Type 2 diabetes, cardiovascular disease, risk factors, 
inflammation, high-sensitivity C-reactive protein 
 
Introduction 
 Type 2 diabetes (T2DM) consists of progressive hyperglycemia, 
insulin resistance, and pancreatic -cell failure (Lin & Sun, 2010). People 
with T2DM are reported to be threefold affected by cardiovascular diseases 
(CVD) compared with those without diabetes (Fonseca, Desouza, Asnani, & 
Jialal, 2004), (Mohieldein, Abdalla, & Hasan, 2014).  Although traditional 
CVD risk factors, such as hypertension and hypercholesterolemia are used to 
assess CVD risk, many have reported their absence in a substantial portion of 
individuals experiencing clinical vascular events (de Ferranti & Rifai, 2007). 
In fact, up to half of those having their first coronary event does not have 
traditional CVD risk factors (Shrivastava, Singh, Raizada, & Singh, 2015).  
Moreover, diabetic patients have not benefited from the advances in the 
management of coronary heart disease (CHD) and/or its risk factors that 
have resulted in a decrease in mortality for CHD patients without diabetes 
(Fonseca, Desouza, Asnani, & Jialal, 2004). This convergence of clinical 
findings supporting the idea that there must be other factors influencing the 
development of CVD end points. Clearly, a more aggressive approach is 
needed to discover additional predictors of risk and incorporate them into the 
traditional risk assessment of CVD (D’Amore, 2005). Among the candidate 
serum markers that might add information to clinical risk assessment is high 
sensitivity C-reactive protein (hs-CRP) measurement which has the most 
potential for clinical use  (de Ferranti & Rifai, 2007), (Yousuf et al., 2013), 
(Grad & Danenberg, 2013). C-reactive protein (CRP) is a 120 kDa acute-
phase protein which is produced mainly in the liver in response to IL-6 
secretion (Ahmed, Jadhav, Hassan, & Meng, 2012), (Ferri et al., 2007). CRP 
is a member of the pentraxin family of proteins that binds to the C-
polysaccharide of Streptococcus pneumoniae (Gang et al., 2012).  
 Novel risk markers for CVD are often said to add independent 
predictive value for risk prediction, based on the finding of a significant 
relative risk after adjustment for traditional risk factors (Lloyd-Jones, Liu, 
Tian, & Greenland, 2006). In the present report we evaluated different CVD 
risk factors based on hs-CRP quartiles. 
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Materials and Methods 
Study design and subjects 
 This is a population- based cross- sectional study of one-hundred and 
nine participants, comprising 64 type 2 diabetics and 45 healthy controls. 
Type 2 diabetics were identified according to American Diabetes 
Association criteria (fasting plasma glucose level ≥ 126 mg/dl (ADA, 2010)) 
or self-reported use of diabetic medication. Healthy non-diabetic subjects 
were recruited from the community; they neither had been diagnosed as 
diabetes nor use hypoglycaemic medication; or any history of known 
disease. 
 
Blood sampling 
 Venous blood sample collected from each subject after an overnight 
fasting in one heparinized vacutainer (4 ml) and one plain vacutainer (4 ml) 
to obtain plasma and serum respectively. HbA1c was performed and after 
centrifugation at 3000 rpm for 15 min, aliquots of plasma and serum were 
separated and stored at -80° C until analysis. 
 
Anthropometric Measurements 
 Body weight and height were measured by trained research assistants 
for all participants. Weight was measured using calibrated electronic 
weighing scales (Proton Digital Scale, Model PHC 309 MD) and height was 
measured using a Portable Height Scale (Mentone Educational, Model 
PE087, Australia).  
 Body Mass Index (BMI) was used to estimate the degree of obesity, 
and was calculated as weight (in kilograms) divided by height (in metres) 
squared using BMI calculator in the website: 
https://www.nhlbi.nih.gov/health/educational/lose_wt/BMI/bmi-m.htm 
 
Measurement of blood glucose 
 Blood glucose was determined based on the glucose oxidase 
peroxidase (GOD- POD) method using commercial kits purchased from 
Human Diagnostics (Wiesbaden, Germany) using Hospitex Eos Bravo 
clinical chemistry analyzer. The glucose was determined after enzymatic 
oxidation in the presence of glucose oxidase. The formed hydrogen peroxide 
reacted under catalysis of peroxidase with phenol and 4-aminophenazone to 
a red-violet quinoneimine dye as indicator. The test linearity was up to 700 
mg/dl. 
 
Measurement of glycated hemoglobin 
 Glycated hemoglobin (HbA1c) was measured on whole blood samples 
by an immunoturbidimetric method using commercial kit (ACC16-048, Vital 
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Diagnostic, Italy). Mouse antihuman HbA1c monoclonal antibody was added 
and latex-HbA1c-mouse anti human monoclonal antibody complex was 
formed. Agglutination was formed when goat anti-mouse IgG polyclonal 
antibody interacts with monoclonal antibody. The amount of agglutination 
was proportional to the amount of HbA1c adsorbed onto the surface of latex 
particles. The amount of agglutination was measured as absorbance. The 
assay range was 0-15% and samples equal to or more than 15% were diluted 
with saline solution and retested.   
 
Measurement of lipid profile 
 Serum total cholesterol (TC), triglycerides (TG) and high-density 
lipoprotein cholesterol (HDL-C) were analyzed using enzymatic methods 
with commercial kits purchased from Human Diagnostics (Wiesbaden, 
Germany). 
 TC was determined based on the cholesterol oxidase- peroxidase 
(GHOD- POD) method. Cholesterol esterase catalyzed the hydrolysis of 
cholesterol esters to produce cholesterol which was oxidized by cholesterol 
oxidase to yield hydrogen peroxide. In a couple reaction catalyzed by 
peroxidase, quinoneimine dye (red) was formed and the absorbance at 546 
nm was proportional to concentration of cholesterol in sample. 
 TG was determined based on the glycerol-3-phosphate oxidase- 
peroxidase (G PO- POD) method. The TG was determined after enzymatic 
hydrolysis with lipases.  Indicator was quinoneimine formed from hydrogen 
peroxide, 4-amino-antipyrine and 4-chlorophenol under the catalytic 
influence of peroxidase 
 HDL-C was determined based on phosphotungstic-precipitation 
method. Briefly, phosphotungstic acid and magnesium ions specifically 
precipitated low and very low density lipoproteins. After centrifugation; the 
cholesterol content of the HDL was determined in the supernatant. 
 Provided serum TG concentrations were less than 400 mg/dl, the 
low-density lipoprotein-cholesterol (LDL-C) was calculated using 
Friedewald formula: [LDL-C = TC - HDL-C - TG/5 (mg/dl)].  
 
Measurement hs-CRP 
 Serum hs-CRP concentration was assayed by a latex 
immunoturbidimetric method using Turbi Quick analyzer (vital Diagnostics, 
Italy) with kits purchased from the same company (Ref: ACC16-025). The 
latex particles coated with specific anti-human CRP were agglutinated when 
mixed with samples containing CRP. The agglutination caused an 
absorbance change, dependent upon the CRP contents of the patient sample 
that was quantified by comparison from a calibrator of known CRP 
concentration.  
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 The linearity limit was up to 5 mg/l. The lower detection limit of the 
assay was 0.05 mg/l. The intra-assay coefficient of variation of the CRP 
levels was 2.0% at 3.0±0.06 mg/l, while the inter-assay coefficient of 
variation was 3.7% at 3.0±0.11 mg/l. CRP levels were categorized into 
quartiles based on the distribution among the controls. 
Measurement apolipoprotein A1 and Apo B 
 Sera ApoA1 and Apo B were measured on Turbi Quick analyzer 
from Vital Diagnostics, Italy. It was based on latex enhance Immuno-
turbidimetric method. We used Apo A1 -B dual control to assess the 
performance of the analyzer. The typical measuring range was up to 700 
mg/dl for both parameters. Sample and reagents were brought to room 
temperature, card provided with reagent were inserted into the analyzer, after 
some time, the analyzer became ready for testing, we run the control in 
control mode and sample in sample mode. 
 
Measurement of blood pressure 
 Systolic blood pressure (SBP) and diastolic blood pressure (DBP) 
were measured prior to drawing blood samples in the sitting position, using a 
standard mercury sphygmomanometer following standard procedure (Milne 
& Pinkney-Atkinson, 2007). Two consecutive readings were recorded for 
each of SBP and DBP and the averages were used. Subjects were defined as 
hypertensive if their systolic blood pressure ≥140 mm Hg or diastolic blood 
pressure ≥90 mm Hg 
 
Statistical Analysis 
 Data were analyzed using the Windows based statistical package for 
social sciences (SPSS) software (version 17, Chicago, IL, USA). Results 
were expressed as mean± standard deviation or number (%) where 
appropriate. Comparison between diabetics and controls was performed with 
unpaired t-tests (for numerical data) and chi-square (for categorical data). 
The P values < 0.05 was considered as statistically significant. 
 
Ethical consideration 
 The protocol of current study was carried according to the Helsinki 
declaration guidelines. Verbal consent was obtained from each subject after 
thoroughly explanation the goals of the study. Participation was voluntary 
and confidentiality of all participants was maintained as no names were 
requested 
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Results 
Baseline demographic and clinical characteristics of the study diabetics 
and controls 
 A total of one hundred and nine subjects were included in this study 
of which sixty-four were type 2 diabetics and forty-five healthy non-diabetic 
subjects. In the patient group, the mean ±SD values for age, HDL-C and 
ApoA1 were 55.5 ±9.5 years, 37.8±3.3 mg/dl and 111.5±15.0 mg/dl  while 
for subjects in control group were 45.9±10.6 years 48.8±4.1 mg/dl and 
130.1±26.3 mg/dl respectively. Moreover, Patients were characterized by 
significantly higher age, BMI, plasma glucose, dyslipidemia when compared 
to controls. 
 Mean serum hs-CRP levels were significantly higher among diabetics 
(2.3 mg/l) compared with controls (1.8 mg/l; P = 0.019). The clinical 
characteristics and laboratory values in study participants with and without 
diabetes were presented in Table 1.  
Table 1. Baseline clinical and laboratory characteristics of the study population 
Variable Controls (n= 45 ) Diabetics (n=64 ) p-value 
Gender (Male/Female) 23/22 22/42 0.081 
Smoking (Yes/No) 10/35 04/60 0.014* 
Education (illiterate/educated) 14/31 40/24 0.000* 
Hypertension (Yes/No) 09/36 36/28 0.000* 
Age, years  45.9±10.6  55.5 ±9.5  0.000* 
Body Mass Index, Kg/m2  28.9 ±5.7 31.9±6.6  0.019* 
Plasma glucose, mg/dl  98.3 ±8.3  225.8±14.5  0.000* 
HbA1c, %  6.4±1.3  8.3±2.2  0.222 
hs-CRP, mg/l   1.8±0.7  2.3±1.4  0.019* 
Total Cholesterol, mg/dl  183.6±13.8  206.1±20.8  0.001* 
Triglycerides, mg/dl  133.5±5.7  156.2±8.6  0.032* 
HDL cholesterol, mg/dl  48.8±4.1  37.8±3.3  0.000* 
LDL cholesterol,  mg/dl  108.1±11.3  137.1±13.1  0.001* 
Apo A1, mg/dl  130.1±26.3  111.5±15.0  0.005* 
ApoB, mg/dl  89.9±15.8  97.8±18.3  0.097 
Values are expressed in mean± SD or number. 
P-values for comparison between controls and diabetics were generated by chi-square (for 
categorical data) and unpaired t-tests (for numerical data) 
 
Risk factor differences across quartiles of hs-CRP among study 
participants 
 Data from study participants showed that the hs-CRP levels were 
≤1.342 mg/l (quartile 1), 1.343 -1.721 mg/l (quartile 2), 1.722 - 2.447 mg/l 
(quartile 3), and ≥ 2.448 mg/l (quartile 4). The third and fourth quartiles of 
hs-CRP were characterized by more frequency of diabetes as well as 
hypertension. The percent of participants with diabetes or hypertension 
apparently seemed to be positively related to hs-CRP concentrations. 
European Scientific Journal November 2017 edition Vol.13, No.33  ISSN: 1857 – 7881 (Print) e - ISSN 1857- 7431 
409 
 In the highest quartile of hs-CRP levels (≥2.448 mg/l), lipid profile 
analysis revealed the highest levels of LDL-C and Apo B compared with that 
in the lowest quartile of hs-CRP levels (< 1.343mg/l) 
 Moreover, participants in the fourth quartile of hs-CRP were 
characterized by the highest age, BMI, plasma glucose. However, there was 
no clear association between levels of hs-CRP and the HbA1c, TC, TG, 
HDL-C, and Apo A. The distribution of the clinical, biochemical, and 
anthropometric characteristics across quartiles of serum hs-CRP was shown 
in Table 2. 
Table 2. The differences in CVD risk factors based on hs-CRP quartiles 
 Quartile CRP (range, mg/l) P-
value 
Risk factor 1st.  
(0.531-
1.342) 
2nd.  
(1.343-
1.721) 
3rd.  
(1.722-
2.447) 
4th. 
(2.448-
9.738) 
 
Sample size, n 26 27 29 27  
Age, years  49.9 ±12.8 52.8 ± 11.1 49.0 ± 9.2 54.7±10.4 0.004* 
Diabetes, n (%) 13 (50) 13 (48.1) 19 (65.5) 19 (70.4) 0.248 
Hypertension, n (%) 8 (30.8 ) 12 (44.4 ) 11 (37.9 ) 14 (51.9) 0.441 
Weight, Kg 70.5±11.6 74.8±17.1 80.3±13.2 85.1 ± 20.4 0.008* 
Height, cm 158.3±22.1 159.2 ±12.1 155.8 ± 15.6 160.7±7.9 0.687 
BMI, (Kg/m2) 28.1±8.4 29.5 ± 4.7 33.1±5.9 33.0 ± 5.3 0.046* 
Plasma glucose, 
mg/dl 
159.8±21.6 139.3±14.1 195.2±18.3 220.6±23.2 0.015* 
HbA1c, % 8.5 ±2.2 8.0±1.9 8.2±2.0 8.2 ± 2.6 0.964 
Triglycerides, mg/dl 145.1±14.8 156.6 ±10.5 137.2±8.2 147.5 ± 7.5 0.635 
Total Cholesterol, 
mg/dl 
193.9 ±22.5 197.5 ±15.3 201.8±24.5 203.5±23.8 0.196 
HDL cholesterol, 
mg/dl 
42.5 ±6.3 40.7±8.4 43.2±6.9 39.9 ±3.8 0.681 
LDL cholesterol, 
mg/dl 
122.4±9.2 125.5 ±8.6 131.2±6.4 134.1 ± 7.8 0.026* 
ApoA1, mg/dl 115.0 ±8.5 125.2±11.8 115.1±17.6 114.3±17.2 0.630 
ApoB, mg/dl 92.7±17.6 94.6 ± 13.4 92.39 ± 14.2 98.5 ± 14.3 0.052* 
Values expressed in mean ± SD or number. 
 
 P-values for comparison between hs-CRP quartiles were generated by 
chi-square (for categorical data) and unpaired t-tests (for numerical data) 
 
Discussion 
 Cardiovascular diseases (CVD), leading cause of morbidity and 
mortality from infancy to old age, are increasing day by day due to over 
utilization of fats or due to genetic reasons (Upadhyay, 2015). CVD are the 
number one cause of death globally: more people die annually from CVDs 
than from any other cause (Al-Mawali, 2015).  
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 In this study, age, BMI, plasma glucose, hs-CRP, total cholesterol, 
triglycerides, and LDL-cholesterol were found to be significantly higher in 
the diabetic patients when compared with the nondiabetic group. However, 
HDL- cholesterol and Apo A1 were significantly low in the diabetics when 
compared to nondiabetic controls.  It has been shown that patients with 
diabetes tend to have a higher body mass index and tend to be glucose-
intolerant, insulin-resistant, and dyslipidemic, with high plasma triglyceride 
and low HDL cholesterol concentrations (Yasunari, Maeda, Nakamura, & 
Yoshikawa, 2002).  
 Despite the irreplaceable utility of plasma lipid profiles in assessment 
of atherosclerotic risk, these profiles provide an incomplete picture. Indeed, 
many cardiovascular events occur in individuals with plasma cholesterol 
concentrations at or below the National Cholesterol Education Program 
thresholds (Packard & Libby, 2008). Among the several biomarkers that 
have been proposed for cardiovascular risk stratification, hs-CRP appears to 
contribute to the identification of people at risk of developing CVD (Fonseca 
& Izar, 2016). Data from the current study confirms that the high hs-CRP 
levels associated with diabetes, that is, the third and fourth hs-CRP quartiles 
characterized by high percent of diabetic patients compared to the lowest hs-
CRP quartiles. In accordance with our finding, Mahajan A et al (2009) 
reported that the median hs-CRP levels were reported to be significantly 
higher in diabetic patients as compared to nondiabetic (P < 0.0001). Elevated 
hs-CRP was positively associated with type 2 diabetes (odds ratio, 1.66; 95% 
confidence interval, 1.21–2.28; P 0.002). In the same line, the Women’s 
Health Study documented that patients in the highest quartile of hs-CRP 
were 4-fold more likely to develop DM than patients in the lowest quartile 
during four years of follow-up (Mazidi, Toth, & Banach, 2017). Recently a 
study in a Japanese population reported that elevated serum hs-CRP was 
associated with an increased degree of insulin resistance, after adjustment for 
traditional risk factors. Moreover, the association of serum hs-CRP with 
insulin resistance was stronger in obese subjects compared to normal weight 
subjects (Uemura et al., 2017). The same finding was documented from our 
study which evident an association between higher levels of hs-CRP 
quartiles and obesity illustrated by that participants in the fourth quartile of 
hs-CRP were characterized by significantly the highest BMI. In consistency 
with the latter finding, Lim et al (2010) reported higher quartiles of CRP 
levels were associated with higher BMI in both the men and the women 
diabetic patients. We can be explained such association of hs-CRP and 
obesity by that IL-6 and TNF-α, which are proinflammatory cytokines 
secreted by adipose tissue, control synthesis and production of CRP (Saijo et 
al., 2004).  
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 Untreated hypertension increases the risk of heart failure, myocardial 
infarction, stroke, aneurysms, kidney failure and damage to retinal blood 
vessels (Subbiah, Chhabra, & Mahajan, 2016). Moreover, recently it was 
reported that individuals who with treated blood pressure management 
strategy (140-149/<90 mmHg) have increased risk of CVD compared with 
those without hypertension (Nayor et al., 2017).  Here we reported high 
percent of hypertension patients was found in fourth hs-CRP quartile which 
supported by Curb et al (2003) who documented that frequency of 
hypertension was as more than doubled in the top versus bottom quartile of 
hs-CRP (19.4 versus 8.4%, P,0.001).  
 Data showed that the highest plasma glucose levels were found in the 
fourth quartiles hs-CRP compared to the lowest quartiles (P = 0.015). In 
favor with this finding, Aronson D et al (2004) reported that diagnosed 
diabetes with impaired fasting glucose has the highest hs-CRP compared to 
subjects with normal fasting glucose. The authors concluded that hs-CRP 
levels increased continuously from the lowest quartile of normal fasting 
glucose level to impaired fasting glucose (P = 0.002 for trend within the non-
diabetic range of fasting glucose) and to diabetes.  
 On the other hand, this study showed no significant association 
between hs-CRP quartile levels and the glycemic control marker, HbA1c. In 
contrast to our finding, recently one study reported that elevated baseline 
plasma CRP levels were associated with an increased risk of type 2 diabetes 
among those already with high HbA1c levels (Pan, Wang, Yuan, & Koh, 
2017). Furthermore, in line with a recent published work (Mazidi, Toth, & 
Banach, 2017), our findings evident that lipid profile parameters LDL-C and 
Apo B were increasing across increasing quartiles of hs-CRP. 
 The characteristics of the fourth hs-CRP quartile with high frequency 
of diabetes, obesity, elevation of LDL-C and Apo B suggests coexistence of 
dysregulated lipid metabolism and inflammation in diabetic patients. 
Therefore, we may expect that patients with type 2 diabetes could be at 
increased risk for CVD and that hs-CRP might be a useful tool and predictor 
for CVD. The acute inflammatory response is an important component in the 
pathogenesis of myocardial injury during acute coronary syndrome and 
endothelial dysfunction is related especially with leukocyte recruitment 
during the formation of the atherosclerotic lesion. The firm union and 
transendothelial migration depend on the interaction between intercellular 
adhesion molecule-1 (ICAM-1), vascular cytoadhesion molecule-1 (VCAM-
1), and the integrins lymphocyte function antigen-1 (LFA-1, CD11a/ CD18) 
and very late activation antigen-4 (VLA-4, CD49/CD29) and the leukocytes 
(Macías, et al., 2003). Serum CRP stimulates endothelial cell expression of 
ICAM-1 and VCAM-1 which are important factors in the development of 
atherosclerosis and may play an important role in promoting the local 
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inflammation within the atherosclerotic plaque (Amran et al., 2011). 
Moreover, elevated blood CRP levels may promote accumulation of 
monocytes in the atherogenic arterial wall by increasing chemotactic 
activities of monocytes in response to monocyte chemoattractant chemokine-
1 (MCP-1) via upregulation of the monocyte chemotaxis receptor CCR2 
(Han et al., 2004).  
 
Conclusion 
 Data from current study showed strong association of the some of the 
traditional risk factors for CVD with the highest quartile of hs-CRP levels 
compared with low levels. The fourth hs-CRP quartile was characterized 
with high prevalence of diabetes, obesity, elevation of LDL-C and Apo B 
which suggests coexistence of dysregulated lipid metabolism and 
inflammation in diabetic patients.  
 It has been reported that CVD onset may happen irrespective to lipid 
profile. Therefore, we may expect that patients with type 2 diabetes could be 
at increased risk for CVD which is one of the macrovascular complications 
of diabetes. 
 We deduced that hs-CRP measurement can provide useful and 
proactive information for development of cardiovascular diseases especially 
among type 2 diabetic patients. Thus hs-CRP can be incorporate into the 
traditional risk assessment of CVD which will help in early intervention to 
prevent the development of CVD among type 2 diabetes. 
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